A Phase 3 Study of the Efficacy and Safety of AR1001 in Participants With Early AD
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi-
center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety
of AR1001 for the treatment of participants with early AD.